Organogenesis/$ORGO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Ticker
$ORGO
Sector
Primary listing
Employees
869
Headquarters
Website
Organogenesis Metrics
BasicAdvanced
$715M
-
-$0.08
1.49
-
Price and volume
Market cap
$715M
Beta
1.49
52-week high
$6.71
52-week low
$2.61
Average daily volume
1.8M
Financial strength
Current ratio
3.319
Quick ratio
2.575
Long term debt to equity
8.037
Total debt to equity
10.573
Profitability
EBITDA (TTM)
19.556
Gross margin (TTM)
74.49%
Net profit margin (TTM)
0.22%
Operating margin (TTM)
0.30%
Effective tax rate (TTM)
116.20%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
0.18%
Return on equity (TTM)
0.30%
Valuation
Price to revenue (TTM)
1.542
Price to book
2.8
Price to tangible book (TTM)
3.3
Price to free cash flow (TTM)
-13.889
Free cash flow yield (TTM)
-7.20%
Free cash flow per share (TTM)
-0.405
Growth
Revenue change (TTM)
2.24%
Earnings per share change (TTM)
39.05%
3-year revenue growth (CAGR)
0.14%
3-year earnings per share growth (CAGR)
-43.99%
What the Analysts think about Organogenesis
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Bulls say / Bears say
Surgical & Sports Medicine net revenue increased 11% year-over-year to $6.8 million in Q1 2025, providing diversification beyond the wound care business. (GlobeNewswire)
Surgical & Sports Medicine net product revenue rose 16% year-over-year to $8.1 million in Q2 2025, reinforcing growth momentum in the sports medicine segment. (BioSpace)
Organogenesis plans to request a pre-BLA meeting with the FDA by the end of October 2025 to discuss the BLA submission pathway for ReNu, underscoring progress toward regulatory approval. (SEC Filing)
Net revenue for Q1 2025 declined 21% year-over-year to $86.7 million, reflecting significant top-line pressure. (GlobeNewswire)
Advanced Wound Care net revenue dropped 23% year-over-year to $79.9 million in Q1 2025, highlighting ongoing challenges in its core wound care portfolio. (GlobeNewswire)
Net loss widened to $18.8 million in Q1 2025 from $2.1 million in the prior year, indicating mounting losses. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Organogenesis Financial Performance
Revenues and expenses
Organogenesis Earnings Performance
Company profitability
Organogenesis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $715M as of November 09, 2025.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 0 as of November 09, 2025.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.